With the increasing prevalence of cardiovascular diseases (CVD) worldwide, finding reliable and clinically relevant biomarkers to predict acute cardiovascular events has been a major aim of the scientific and medical community. Improvements of the understanding of the pathophysiological pathways of the disease highlighted the major role of lipoprotein particles, and these past decades have seen the emergence of a number of new methodologies to separate, measure and quantitate lipoproteins. Those methods, also known as advanced lipoprotein testing methods (ALT), have gained acceptance in the field of CVD risk assessment and have proven their clinical relevance. In the context of worldwide standardization and harmonization of biological assays, efforts have been initiated toward standardization of ALT methods. However, the complexity of lipoprotein particles and the multiple approaches and methodologies reported to quantify them have rendered these initiatives a critical issue. In this context and to better understand these challenges, this review presents a summary of the major methods available for ALT with the aim to point out the major differences in terms of procedures and quantities actually measured and to discuss the resulting comparability issues.
Introduction
Cardiovascular diseases (CVD) are the first cause of premature mortality in the world and represented 46.2% of the deaths attributed to noncommunicable diseases in 2012 [1] . The complexity of the pathophysiological pathways underlying CVD and its multifactorial origin lead health authorities and scientific organizations to recommending global approaches to evaluate a patient risk profile. These first involve estimating major risk factors such as age, sex, smoking or hypertension, and predisposing factors such as familial background. Additional analyses to measure concentrations of the circulating lipid blood markers, i.e. total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG), are then recommended in order to establish a 10-year risk profile [2] [3] [4] .
However, as patient with low risk profiles still experience acute CVD events and because cholesterol and LDL-C lowering therapies only decrease the risk by about a half, the remaining residual risk for acute CVD events is significant [5] [6] [7] . Other lipoprotein-related factors and non-lipid-based markers have thus been sought over the years in order to provide physicians with more predictive biomarkers for CVD risk assessment [8] . In this search, the importance of lipoprotein particles themselves in the atherosclerosis pathway, rather than their lipid content, was evidenced and different biomarkers emerged. For instance, increased concentrations of lipoprotein(a) were found to be causally related to premature CVD [9] [10] [11] [12] , and a strong correlation between elevated concentrations of apolipoprotein B (apoB) and CVD risk was evidenced [13] [14] [15] . It has also been demonstrated that small-dense LDL (sd-LDL) particles tended to be more atherogenic and were associated with premature CVD events [16] [17] [18] [19] [20] . Low-density lipoprotein particle number (LDL-P) was additionally found to be a good predictor of patients risk of developing atherosclerosis [19, 21, 22] .
Historically, the major lipoprotein classes were defined according to their densities using ultracentrifugation (UC) and LDL-C and HDL-C concentration cutoffs for treatment were defined using UC-separated lipoproteins [23] . However, lipoproteins can also be separated based on their electrophoretic mobility [24] or according to their apolipoprotein content [25] . These methods have been extensively studied and developed to further separate lipoproteins and establish lipoprotein profiles [26] [27] [28] [29] . For instance, gradient gel electrophoresis (GGE) using gels of increasing concentrations, i.e. of decreasing pore size, separates lipoproteins according to both their size and charge. Various methodologies exist to detect and quantify lipoprotein fractions afterward, but most of them rely on specific lipid staining or lipid-targeting enzymatic reactions [27, 28] . Analytical procedures based on capillary electrophoresis or isotachophoresis were also reported in the late 1970s but were sparsely implemented for routine analyses [27, 30] .
On the contrary, apolipoprotein quantification by immunoassays such as immunonephelometry (IN), immunoturbidimetry (IT) and enzyme-linked immuno-sorbent assays (ELISA) were widely implemented in clinical laboratories [29, 31] . Indeed, the full automation and the lower cost of these assays allow high throughput analyses with acceptable precision and are, to date, the methods of choice for routine lipoprotein testing. Nevertheless, the high interest in lipoprotein profiling resulted in the development of a number of additional methods known as advanced lipoprotein testing (ALT) methods. These new approaches rely on various separation principles that use different characteristics of lipoproteins to establish lipid and/or lipoprotein profiles, for example, their lipid content, apolipoprotein content or size. The wide differences of measurement protocols then raise important questions: Are these ALT methods able to provide comparable lipid profiles? Is one of these methods more relevant than others for CVD risk assessment?
During the past 20 years, many clinical trials and large prospective studies have involved ALT methods in order to address these questions [32] [33] [34] . However, results of these studies are conflicting and evidence still lacks to support the use of ALT methods in current clinical practice [35] . In addition, comparability of data provided by different ALT methods has been sparsely studied, and it can be expected that two methods measuring differing quantities in differing ways, or methods measuring a same quantity in differing ways, may not provide comparable results. This specific concern is of major importance for worldwide harmonization and standardization as a lack of comparability could result in differing diagnostics and medical decision making. The Joint Committee for Guides in Metrology published an international vocabulary for metrology (VIM) guide that defines the measurand as the quantity intended to be measured by a measurement system in specific conditions [36] . Therefore, with respect to this definition, different systems aiming at measuring the same entity can involve differing measurands. In such cases, results comparability ought to be verified.
This review presents the most recent approaches reported for ALT in terms of methodologies for separation and detection of lipoproteins with the aim to evidence what each of these methods really measures. Metrological status, result traceability differences and resulting comparability issues are also discussed in this review.
Review of ALT methods

Tube gel electrophoresis (TGE)
Since the first publications reporting lipoprotein separation on gel matrices in the early 1960s [37] , gel electrophoresis (GE) underwent numerous developments and optimizations, especially concerning gel preparation, electrophoretic separation and staining. GE separates lipoproteins according to both their size and charge on gels of different natures. Depending on charge, particle mobility is more or less enhanced by the electric field while, in parallel, size hinders the migration in the gel network so that large particles migrate less than small ones. The main disadvantages of GE are the poor resolution and reproducibility of lipoprotein separation, notably due to the large variability of gel quality, and it is often considered a semiquantitative method [27] . However, the commercialization of ready-to-use tubes for GE (TGE) with reproducible gel matrices of similar properties, furnished as kits, greatly improved the method robustness.
LIPOPRINT™ is an example of semiautomated TGE system commercialized by Quantimetrix (Redondo Beach, CA, USA) for lipoprotein separation. The method involves GE kits, either specific to LDL or HDL particles profiling, consisting of ready-to-use 3% precast polyacrylamide gels in individual tubes [38] . Using a cholesterol-specific dye added before electrophoresis, lipoproteins, separated as different bands in the gel, are detected by densitometry to obtain the lipoprotein profile. In addition, because the dye added is cholesterol specific, bands intensity, i.e. the peak area determined by densitometry, is proportional to the relative amount of cholesterol associated with each lipoprotein subclass. This relative amount, when multiplied by the TC concentration, then corresponds to the absolute cholesterol concentration associated with each lipoprotein subclass [38, 39] . The major advantage of this method is that it comes with automated data processing software that posttreats densitometric measurements to determine the relative amounts of the different lipoprotein fractions. However, TC concentrations have to be measured separately with an independent method prior to analyses. Lipoprotein profiles are obtained in less than 3 h and compare well with those obtained by polyacrylamide GGE [38, 40] . The system was actually cleared by the FDA for LDL-C and LDL subfraction cholesterol concentration measurements [41] . The system can additionally measure lipoprotein sizes; however, comparability of the diameters obtained by this technique and by classic GGE was found perfectible [40, 42] .
Cholesterol subclass concentrations measured after TGE rely on densitometry measurements. Depending on the method chosen to reveal lipoproteins after separation, the quantity actually measured is different. If a lipid or lipoprotein dye is used, the measurand is the complex formed between the dye and its target. However, if an enzymatic assay is used, then the measurand is the colored product of the reaction between the enzyme and its substrate. Very few data are available on the calibration materials used for particle concentration measurements derived from electrophoretic techniques, and most assays seem to have been developed using materials value assigned by field methods such as IT [38, 43] . However, for LIPOPRINT™, TC concentrations must be measured independently. If they were determined by a primary reference method, then the derived concentrations would be traceable to the SI units. It is to keep in mind though that because measurands are different, establishing SI traceability of the TC concentration would not guarantee the accuracy of the derived lipoprotein fractions cholesterol concentrations.
Gel permeation (GP) chromatography
Gel permeation-high-performance liquid chromatography (GP-HPLC) was first reported in 1980 by Hara et al. [44] , and its clinical relevance to distinguish different lipoprotein profiles in serum was demonstrated shortly after [45, 46] . Recently, an automated GP-HPLC system adapted for routine and high throughput measurements of lipoprotein profiles, notably involving automated data processing, was released as the LipoSEARCH ® [47] . GP-HPLC separates lipoproteins as a function of their hydrated diameter according to size exclusion chromatography (SEC) principles. The large column pores allow the permeation of the smallest entities inside the pores while the biggest entities are not able to penetrate. Largest entities are thus eluted first as their path through the column is the shortest while the smallest entities elute last as their path through the pores is longer [48] . Detection and quantitation are performed using UV-Visible absorbance, either at 280 nm for apolipoproteins or at 550 nm after lipid derivatization [49] . LipoSEARCH ® uses two tandem TSK-like columns packed with polymethacrylate beads and measures simultaneously cholesterol and TG concentrations of the separated lipoproteins. Detection is performed by absorbance at 550 nm after enzymatic reaction of TG and cholesterol [50] . Automated data-processing software then deconvolutes chromatographic peaks and calculates the lipid concentrations associated with each lipoprotein subclass. Corresponding particle numbers can additionally be derived by the dedicated software using an algorithm developed and patented by Okazaki in 2015 that calculates particle number concentrations from TG and cholesterol concentrations and particle size [50, 51] .
Similar techniques using fast protein liquid chromatography (FPLC) systems for lipoprotein profiling were also reported in the late 1980s. These methods also separate lipoproteins by SEC, i.e. according to their size, but on a different type of resins: agarose gel Superose 6 [49, 52, 53] . Lipoprotein profiling and quantification protocols using these systems are similar to that of GP-HPLC. However, an important value added of FPLC is the possibility to use it either as an analytical or preparative method with improved reproducibility compared to UC [54] . Longer analyses procedures, lower throughput and higher pressures are the major downsides of FPLC. The method thus sparsely spread as a routine technique but does constitute a valuable tool for complementary analyses in research facilities or for clinical studies.
Concentration measurements by GP-HPLC or FPLC are performed mostly by continuous enzymatic reactions of cholesterol and TG or by absorbance measurements of the apolipoproteins at 280 nm. Overall, most methods described for lipoprotein profiling by GGE can be used for detection and quantification after GP lipoprotein separation. Assay calibration then depends on the method chosen to assign the TC and/or TG concentrations to the control materials. In parallel, GP columns pore size are generally verified using the same materials used for pore size calibration in GGE, i.e. either nanoparticle standards or protein molecular weight standard mixtures [55] .
Apolipoprotein profiling by liquid chromatography isotopic-dilution mass spectrometry (LC-ID/MS)
Isotopic-dilution mass spectrometry (ID/MS) is the higher order reference method for many biomarkers in clinical chemistry and notably for TG and TC measurements [56, 57] . Apolipoprotein quantification by liquid chromatography ID/MS (LC-ID/MS) was first reported in the late 1990s by Barr et al. for apoA-I [58] and was further applied to other apolipoproteins (apoB, C and E) in the following years [59] [60] [61] .
Apolipoprotein absolute quantification by LC-ID/MS relies on enzymatic trypsin digestion of serum apolipoproteins. After digestion, apolipoprotein-specific tryptic peptides were identified for each major class of apolipoproteins, and some of them were selected for quantification by ID/MS [60] [61] [62] . ID/MS quantification uses synthetic labeled entities with 13 C, 15 N or deuterium as internal standards (IS) to spike the samples. Depending on the method, this IS can be either the labeled recombinant protein or a synthetic labeled peptide characteristic of the protein. In the first case, both calibrators and samples undergo digestion, whereas in the latter case only the samples are digested. Using a recombinant protein as IS is considered the best practice for accurate and precise protein quantification by ID/MS as it allows taking into account the variability due to digestion. However, in some cases, using recombinant proteins is a challenge, and the alternative solution involving a synthetic peptide is more adapted. For quantification, calibrators consist of mixtures of unlabeled and labeled standards, i.e. protein or peptide, in different molar ratios. The peak area ratio of the unlabeled versus labeled entity is plotted as a function of the molar ratio to obtain the calibration curve. Knowing the concentration of the synthetic standards, the concentration of the endogenous peptide after digestion can be derived by calculating the peak area ratio of the endogenous peptide versus labeled peptide in the sample.
Although ID/MS results usually are reproducible and accurate, the initial tryptic digestion step may increase results variability, especially when using peptides as IS. The choice of fast releasing peptides and the verification that digestion is complete are then necessary to achieve accurate and precise quantification [63] . In addition, to establish the calibration curve, concentrations of the IS have to be accurately measured. This can be done with a primary reference method such as amino acid analysis by ID-LC/MS, using high purity amino acid certified reference materials (CRMs) as calibrators. Then, results of apolipoprotein quantification can be traceable to the SI units via an unbroken traceability chain. However, the only available reference materials (RMs) for apolipoprotein quantification were produced in the early 1990s to harmonize IN and IT assays [64] . These materials were endorsed by the World Health Organization (WHO) and widely used to recalibrate routine apolipoprotein immunoassays but were never intended for standardization purposes. It appears nevertheless that most ID-LC/MS methods for apolipoprotein quantification use these WHO RMs as external calibrators [60] [61] [62] .
Given its high accuracy, good comparability with IN assays [59, 60] , possible SI traceability and high throughput, ID-LC/MS is one of the candidate reference methods for apoB and apoA-I quantification in serum. However, this method uses expensive materials, and although "turn-key" approaches have been reported [62] , ID-LC/MS requires trained technical staff and dedicated instrumentation. This method is thus mostly used for research purposes and has neither been involved in clinical studies nor transferred to clinical laboratories for routine.
Vertical auto profile (VAP ® )
Vertical auto profile (VAP) was developed in the 1980s by Chung et al. [65] and Cone et al. [66] and is a semiautomated system which protocol was derived from lipoprotein separation by sequential UC. The system underwent various optimizations and was commercialized by Atherotech (Birmingham, AL, USA) until 2016 in different upgrades: VAP-II-fingerstick ® (VAP-II-fs), which provides the lipoprotein profile of a patient from a minimum amount of plasma (18 μL) [67] , and VAP-II, a similar system with better resolution and performances that however necessitates larger amounts of plasma [68] .
VAP-II ® analysis is a two-step procedure. First, lipoproteins are separated by Single Vertical Spin densitygradient UC [65, 69] . Plasma density is adjusted with KBr to a density equal to, or greater than, the densest lipoprotein to be separated. This density-adjusted plasma is then introduced into a centrifuge tube and layered under a KBr or NaCl solution of density equal to, or lower than, the density of the least dense lipoprotein to be separated. The tube is then ultracentrifuged in a vertical rotor at approximately 720,000 g for an hour. The discontinuous gradient ensures the sufficient separation of lipoproteins according to their respective flotation rates: a function of their density, size and conformation. The densest ones thus end up in the bottom of the tube, whereas the least dense ones are in the upper zone of the tube [69] . These separated lipoproteins are then quantified using their cholesterol content with an automated continuous enzymatic assay. For that purpose, the centrifuge tubes are placed in a gradient fractionator, and the gradient is continuously drawn from the tube and mixed in a chamber with an enzymatic cholesterol reagent. Absorbance is then measured at 505 nm [65] . The continuous measure of the absorbance is reported as a function of the relative gradient position, and deconvolution of the signal by software-assisted data processing finally allows the determination of the cholesterol concentration associated with each lipoprotein class and subclass, thus providing the lipoprotein profile [66] . Additionally, cholesterol concentrations can be further converted into apoB-equivalent concentrations via an algorithm included in the software [70] .
VAP-II ® targets the cholesterol contained in lipoproteins using a specific enzymatic assay. The quantity measured is thus the colored product of the reaction between cholesterol and enzymatic reagent. Method linearity and reproducibility proved to be satisfactory with coefficients of variation lower than 5% for TC and for cholesterol subclasses concentrations [71] . Concerning accuracy, VAP-II LDL-C concentrations were compared to those measured with the Abell Kendall method at the Northwest Lipid Research Laboratory (NWLRL, Seattle, WA, USA), a reference laboratory for cholesterol measurements. Results were found in good agreement [71] . Concerning apoB concentration measurements by VAP-II, the equations involved to convert cholesterol concentrations into apoB equivalents were determined by correlation with an IT assay calibrated with the WHO RM for apolipoproteins [70] rendering apoB concentrations by VAP traceable to this material.
Nuclear magnetic resonance (NMR)
In 1991, Otvos reported a new method for lipoprotein quantification using a spectroscopic method: proton nuclear magnetic resonance (H-NMR) [72] . This method was automated and commercialized as the NMR LipoProfile ® (LabCorp, Burlington, NC, USA) assay and was recently cleared by the FDA for cholesterol concentration measurements [73] . Its clinical relevance for CVD risk assessment was demonstrated several times in the context of clinical trials [15, 21, 32] . Very recently, a new two-dimensional H-NMR assay, the DOSY LipoScale ® (Biosfer Teslab, Tarragona, Spain), was also developed for lipoprotein quantification [74, 75] .
When submitted to a high-frequency magnetic field, protons contained in molecules or proteins produce resonance spectra that are specific to their chemical environment. It was evidenced by Otvos et al. that lipoproteins in plasma had specific resonance signatures [76] , and Lounila et al. demonstrated a relationship between H-NMR resonance frequency and lipoprotein diameters [77] . Lipoprotein H-NMR spectroscopy measures the specific resonance signature of the particles' lipid terminal methyl groups [78] . Otvos suggested an interesting analogy with bells to further explain NMR principles [72] . Similarly to bells of different size having different sound signals, different lipoproteins broadcast different lipid signals depending on their size. In addition, as the sound loudness is expected to be proportional to the number of bells, the amplitude of the lipid resonance signal is expected to feature the amount of lipids in the particle. H-NMR analysis thus deconvolutes a composite sound signal of lipoproteins in plasma to extract their specific signal and amplitude, i.e. respectively their diameter and concentration.
LipoProfile ® was the first available assay for lipoprotein quantification by H-NMR. It uses a linear least square regression model to deconvolute the H-NMR spectra measured [79] . To reconstruct the different peaks corresponding to each lipoprotein class and subclass, this software relies on a library of lipid H-NMR spectra obtained from lipoprotein fractions prepared by UC and further characterized in size and lipid composition using GGE or electron microscopy and chemical analyses [78] . Particle concentrations are then expressed either as TG or TC concentrations [72] , and results can be extracted afterward as a proprietary test report adapted for physicians and detailing lipid concentrations and risk status.
Recently, a new alternative to H-NMR spectroscopy was suggested using 2D diffusion-ordered H-NMR spectroscopy (DOSY) and was patented as a new assay for lipoprotein quantification: the LipoScale ® [74, 80] . This method measures H-NMR spectra under a strength gradient resulting in changes in the H-NMR resonance intensities. These changes depend notably on the diffusion coefficient of the species that generate the resonance. Lipoprotein diffusion coefficients are estimated by DOSY and derived as hydrated radii using the Stokes-Einstein equation [81] . DOSY cholesterol concentrations of lipoprotein subclasses are calculated using the same principle as 1D-H-NMR, i.e. using data-processing software similar to that of LipoProfile ® . This software was however further developed and modified to improve peak deconvolution using statistical approaches [82] .
H-NMR thus measures proton resonance of lipids contained in lipoproteins. As this resonance is produced by all lipids in the particle, it is often considered that H-NMR directly measures lipoprotein particles. H-NMR requires trained technical staff and dedicated instrumentation, but the development of automatic and affordable assays for lipoprotein profiling has enabled its widespread use in clinical trials [15, 21, 32, 83] . Absence of lipoprotein separation steps and short run times have made H-NMR one of the most used ALT methods for clinical trials and research over these past decades. However, H-NMR measures lipid concentrations by resonance and derives this concentration further into lipoprotein particle concentrations, relying on the hypothesis that a fixed mean quantity of lipids is contained in each lipoprotein. In addition, lipoprotein quantification accuracy largely relies on the processing software used for signal deconvolution which processes highly complex spectra using an experimental library. No data were found on the way processing algorithms were established nor on system's calibration and therefore, traceability of the results remains unclear.
Electrospray differential mobility analysis (ES-DMA)
Electrospray differential mobility analysis (ES-DMA), also known as ion mobility analysis, is the most recent ALT method. First reported in 1998 by Kaufman, it was initially applied to nanoparticle and macro-ion size measurements [84] . Its first application to lipoprotein profiling was reported in 2008 in a publication by Caulfield et al. [85, 86] . This method is now available as a routine diagnostic test exclusively run by Quest Diagnostics (Madison, NJ, USA) and has already been involved in clinical trials [33, 87] .
ES-DMA is a system that selects and counts intact lipoprotein particles in the aerosol phase. Lipoproteins in serum are aerosolized with an electrospray interface including a neutralization source used to apply a known charge distribution to the generated aerosol. Downstream, aerosolized lipoproteins are selected using a differential mobility analyzer (DMA) composed of a drift tube in which lipoproteins, submitted to an electric field ramp at atmospheric pressure, are selected gradually depending on their electrical mobility diameter. The selected lipoproteins are then counted by laser detection in a condensation particle counter [88] . Finally, results are reported as a number size distribution that represents the number of particles counted per cubic centimeter of air at each mobility diameter. Integrating the peaks of interest, i.e. summing all counts on a diameter range, thus provides the particle concentration measured by the system in the aerosol phase. However, the key step for particle number quantification by ES-DMA is the postanalytical processing to further derive this aerosol phase particle concentration into a liquid phase particle concentration, i.e. the concentration in the initial sample. Various approaches have been reported, but to date, debates remain concerning the most adapted method and harmonization of the process have not yet been achieved [86, 89, 90] .
Although ES-DMA has proven its relevance for lipoprotein testing, it has been very little implemented in clinical and research laboratories. Indeed, although automation and high throughput proved to be achievable for ES-DMA, these remain costly and require expert technical staff. In addition, ES-DMA is sensitive to interferences, especially generated by serum proteins, and specific sample preparation steps are often necessary to obtain an accurate lipoprotein profile. Nevertheless, one advantage of ES-DMA is that it measures in a short time the full lipoprotein profile of the sample without data deconvolution. Lipoprotein classes may not be fully resolved, but their concentrations can be calculated over specified diameter ranges [86] . Contrary to most methods reported for lipoprotein profiling and quantification, ES-DMA is the only one for which the measurand is the full intact lipoprotein [91] . However, it was demonstrated that calibration with appropriate standards is necessary to achieve accurate quantification and a study of results comparability with IN revealed important variability depending on the calibration material chosen [90] . As for diameter measurement accuracy, ES-DMA systems are generally calibrated with CRMs of inorganic nanoparticles and provide highly precise measurements [90, 92] . It is however important to note that the diameters measured with ES-DMA are electrical mobility diameters, i.e. dry diameters, which can therefore not be compared to hydrated diameters such as ones measured by GGE.
Comparability of ALT methods and related issues
Lipoprotein particles are well known for being extremely complex entities of various densities, sizes, compositions and functions [25] . As evidenced in this review, the list of available methods for lipoprotein profiling is long, although not exhaustive. Table 1 shows a sum-up of all methods detailed above, including for each of them lipoprotein separation principles, sample preparation steps, detection and quantification principles and results traceability [18] .
A first general issue regarding comparability of ALT methods is related to the different measurands each of [42] . This intercomparison demonstrated that only three among 39 patient samples were classified as having the same LDL phenotype, i.e. only ≈8%. In 2011, a comparison of apoB concentrations measured by VAP, NMR and IN with non-HDL-C measurements on the SAFARI (Simvastatin plus Fenofibrate for combined hyperlipidemia) cohort was published by Grundy et al. [93] . It reported perfectible agreement between the methods and inconsistencies of apoB concentrations derived by each method. In 2013, Cole et al. [15] reported the results of a meta-analysis including 25 clinical studies comparing the clinical significance of IN apoB concentrations and LDL-P concentrations measured by NMR LipoProfile ® . Results revealed only 58.8% agreement of apoB and LDL-P biomarkers in their association with diverse clinical outcomes. The two methods were additionally compared in terms of analytical performances, cost-effectiveness and possibility for high throughput, but no conclusions were drawn concerning results comparability.
A second general issue regarding comparability of ALT methods is the lack of standardization. In the late 1990s, the joint efforts of the International Federation of Clinical Chemistry and Laboratory Medicine, the Centers for Disease Control (CDC) and the NWLRL led to the successful harmonization of IN and IT assays via the production of RMs for apolipoprotein testing [94] . A lyophilized, serum-based material was endorsed by the WHO as ApoA-I RM. It was value assigned by IN and is traceable to the SI through amino acid analysis of a primary RM made of purified ApoA-I [64] . ApoB RM is a stabilized, frozen, serum-based material and, contrary to ApoA-I, its assigned value is not traceable to the SI [95] . Indeed, the physicochemical properties of purified ApoB and its propensity to aggregate when purified rendered the production of a stable primary calibrator a challenge. A solution of purified LDL particles prepared by UC was thus chosen instead, and its ApoB concentration was assigned by IN using a fresh solution of purified apoB-100 as calibrator [95, 96] . The IN assay used then was developed with an antibody specifically raised against ApoB-100 and thus does not measure ApoB-48, which is mainly present in chylomicrons [97] . Thanks to these standardization initiatives, IN and IT assays were successfully harmonized and the WHO RMs SP1-01 (ApoA-I) and SP3-08 (ApoB) remain, to date, the only available RMs for apolipoprotein quantification. However, the other ALT methods developed were not concerned by these initiatives, and neither standardization nor harmonization have been achieved for these assays. Nevertheless, as Table 1 evidences, a number of them use the WHO RMs as standards to ensure results traceability, although some assays, especially GE and GP-HPLC, use UC prepared lipoprotein fractions, valueassigned for TC or TG concentrations, as calibrators. The use of different calibrators thus implies that results traceability chains are different and that, consequently, they may not be comparable.
During the past decades, research efforts have concentrated on identifying new biomarkers that could better predict the risk for a patient to develop CVD. A substantial number of clinical and prospective studies have been reported with the intent to demonstrate the relevance of one specific biomarker of these diseases. However, results of these studies are largely questioned, especially concerning the relevance of apoB or LDL-P measurements. Many professional organizations published guidelines for the management of CVD risk and debates remain concerning ALT methods and especially apoB [35, [98] [99] [100] . Indeed, the latest guidelines do not necessarily recommend the use of ALT methods for patients risk management and most reviews on ALT methods relevance conclude that there is no sufficient evidence to promote their use in routine [4, 14] . Consequently, most regulatory bodies worldwide do not recommend the use of ALT methods, unless very specific dyslipidemias are met. Indeed, in cases of severe dyslipidemias, LDL-C concentrations cannot be measured accurately with routine procedures and most physicians then turn to ALT methods to obtain complementary data. Moreover, some assays have recently received clearance from regulatory bodies, especially in the USA [41, 83] , which highlights that, although authorities remain skeptical on their clinical relevance, ALT methods can provide valuable information.
Concluding remarks
As highlighted in this review, a number of methodologies are available to characterize lipoprotein profiles. However, given the broad interest of these methods for patient diagnosis and follow-up, especially with respect to the increasing prevalence of CVD worldwide, data on relevance and results comparability appear necessary. From a metrological and regulatory perspective, establishing traceability chains and SI traceability of lipoprotein classes and subclasses concentration measurements is of major importance. In the light of the information concerning calibration materials used for each method (Table 1) , it however appears that most assays are already using the same materials as calibrators. Harmonization of the results to a unique RM material, although not traceable itself to the SI reference system, is a first step toward comparability, an important prerequisite being that the RMs are commutable for the concerned methods. Nevertheless, actual data are lacking, and neither harmonization nor standardization will be achievable until comparability is empirically assessed.
In clinical laboratories, IN and IT are the methods of choice with respect to their full automation, high throughput and acceptable precision. From this perspective, the use of most ALT methods is not yet conceivable for routine analyses because most of them are neither cost-effective nor easily automatable for high throughput. Nevertheless, ALT methods do provide valuable information for research purposes, and it seems that their true potential has not yet been fully explored. Additionally, it could be expected that assay standardization resulting in good comparability of the results would help clarifying the relevance of lipoprotein profiling for CVD risk management. However, standardization would require the choice of a reference method providing SI-traceable results to value-assign primary calibrators, which raises the question: Which of these ALT methods to choose? As we tended to evidence in this review, the different measurands on which ALT assays rely render standardization efforts challenging. There is no evidence, nor reason yet, to rather choose one method over another, and just as combining different photos from different points of view, ALT methods provide different but complementary information on a patient's risk profile.
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